Northwestern Mutual Wealth Management Co. Sells 14,738 Shares of Novo Nordisk A/S $NVO

Northwestern Mutual Wealth Management Co. lowered its position in shares of Novo Nordisk A/S (NYSE:NVO) by 7.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 174,408 shares of the company’s stock after selling 14,738 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Novo Nordisk A/S were worth $8,874,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Guerra Advisors Inc purchased a new stake in Novo Nordisk A/S in the third quarter worth approximately $25,000. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S in the fourth quarter worth approximately $25,000. Strengthening Families & Communities LLC purchased a new stake in Novo Nordisk A/S in the third quarter worth approximately $30,000. WealthCollab LLC boosted its holdings in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after purchasing an additional 260 shares during the last quarter. Finally, American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the fourth quarter worth approximately $28,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.6%

Shares of Novo Nordisk A/S stock opened at $42.93 on Wednesday. The company’s fifty day simple moving average is $41.12 and its 200-day simple moving average is $46.34. The stock has a market capitalization of $191.70 billion, a PE ratio of 10.08, a P/E/G ratio of 3.93 and a beta of 0.78. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The business had revenue of $10.85 billion for the quarter. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.46 earnings per share for the current year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk said its Wegovy pill will launch in the UAE after receiving regulatory approval, another sign that its oral obesity treatment is gaining international traction. Novo Nordisk’s Wegovy Pill to Launch in the UAE Following Regulatory Approval
• Positive Sentiment: Novo Nordisk announced a partnership with NOVI Health in Singapore to expand access to structured weight-care support, which could help broaden adoption of its obesity treatments. NOVI Health Partners with Novo Nordisk to Expand Access to Structured Weight Care Support in Singapore
• Positive Sentiment: Novo Nordisk continued its share repurchase program, a move that can support earnings per share and signal management confidence. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Investors are also watching Novo Nordisk ahead of the ADA conference, where any new diabetes or obesity updates could influence sentiment. Is Novo Nordisk A/S (NVO) Expanding Its Lead in Diabetes and Weight Loss Ahead of ADA Conference?
• Neutral Sentiment: Analysts are highlighting broader long-term growth potential in GLP-1 drugs, but this is more of a thematic backdrop than a direct catalyst. 5 Best Growth Stocks for the Next 10 Years (NVO)
• Negative Sentiment: Eli Lilly regained CVS Health’s support for GLP-1 access, which may weaken Novo Nordisk’s competitive position in the U.S. obesity-drug market. Eli Lilly Wins Back CVS Health, Reverting Novo’s Advantage (NVO)
• Negative Sentiment: Tracking data suggests Wegovy’s oral version is still leading Lilly’s rival tablet, but weekly prescription growth is slowing as competition heats up in the GLP-1 space. Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on NVO shares. Morgan Stanley upgraded shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a report on Tuesday, March 3rd. Deutsche Bank Aktiengesellschaft cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, February 23rd. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. TD Cowen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price on the stock. in a report on Tuesday, March 10th. Finally, Wolfe Research started coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Four investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.